title: Taking part in a pharmacogenetic clinical trial: assessment of trial participants understanding of information disclosed during the informed consent process.
abstract: BACKGROUND
  This study is the first to examine the understandings that participants have of the consent process in a pharmacogenetic trial of anti-depressant medication.
  
  
  METHODS
  This was a qualitative cross sectional study. There were 76 participants residing in London, Mannheim, Arhuus and Poznan.
  
  
  RESULTS
  Only one quarter of participants (none in Poznan) could articulate the concept of pharmacogenetics. Heritability and testing medication were also given as the purpose of the trial. Most participants had not appreciated harms that could derive from the trial. Even when shown the consent sheet, participants were confused about DNA profiling. There was evidence that participants appreciated weekly contact with researchers. Most said they would participate in a trial again but would like choice over the intervention they were assigned to.
  
  
  CONCLUSIONS
  Participants in this study showed a poor level of informed consent. Although this is not the first time this argument has been made, it is in the case of a pharmacogenetic trial. Further work should investigate the associations between extraneous factors such as information and social support on beneficial or untoward outcomes of antidepressant treatment.
authors.affiliation: Institute of Psychiatry, King's College London, de Crespigny Park, London SE5 8AF, UK. diana.rose@kcl.ac.uk.
authors.forename: Diana
authors.initials: D
authors.lastname: Rose
authors.forename: Jasna
authors.initials: J
authors.lastname: Russo
authors.forename: Til
authors.initials: T
authors.lastname: Wykes
mesh_terms: D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic / Q000941:ethics*; D032882:Comprehension / Q000941:ethics; D003430:Cross-Sectional Studies; D016172:DNA Fingerprinting; D004522:Educational Status; D005260:Female; D005858:Germany; D006801:Humans; D007258:Informed Consent / Q000941:ethics / Q000523:psychology / Q000706:statistics & numerical data; D008131:London; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D010597:Pharmacogenetics; D011044:Poland; D036301:Qualitative Research; D035842:Research Subjects / Q000523:psychology; D035844:Researcher-Subject Relations / Q000941:ethics / Q000523:psychology; D014342:Truth Disclosure
references.citation: Pharmacogenomics J. 2009 Aug;9(4):225-33
references.pmid: 19365399
references.citation: Soc Sci Med. 2004 May;58(9):1689-97
references.pmid: 14990370
references.citation: Int J Law Psychiatry. 1982;5(3-4):319-29
references.pmid: 6135666
references.citation: J Med Ethics. 2002 Jun;28(3):151-5
references.pmid: 12042398
references.citation: Pharmacogenomics J. 2006 Sep-Oct;6(5):289-95
references.pmid: 16550208
references.citation: Am J Psychiatry. 2004 May;161(5):797-806
references.pmid: 15121642
references.citation: Ann Oncol. 2000 Aug;11(8):939-45
references.pmid: 11038029
references.citation: Psychiatr Serv. 1999 Jul;50(7):961-3
references.pmid: 10402622
references.citation: Curr Opin Psychiatry. 2005 Mar;18(2):111-9
references.pmid: 16639163
references.citation: Br J Cancer. 1995 Jun;71(6):1270-4
references.pmid: 7779722
references.citation: J Clin Oncol. 1996 Mar;14(3):984-96
references.pmid: 8622050
references.citation: J Med Ethics. 2006 Aug;32(8):439-43
references.pmid: 16877621
references.citation: Sociol Health Illn. 2008 Sep;30(6):944-58
references.pmid: 18761513
references.citation: J Mol Med (Berl). 2004 Jan;82(1):21-30
references.pmid: 14598045
references.citation: Am J Psychiatry. 1999 Sep;156(9):1380-4
references.pmid: 10484948
references.citation: Arch Gen Psychiatry. 1997 Feb;54(2):113-6
references.pmid: 9040277